Zevra Therapeutics (ZVRA) Receivables (2016 - 2026)

Zevra Therapeutics' Receivables history runs 11 years deep, the most recent figure standing at $22.1 million for Q1 2026.

• Quarterly Receivables rose 75.14% year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (up 75.14% YoY) and the FY2025 annual result came in at $23.3 million, up 114.52% from the prior year.
• Receivables was $22.1 million for Q1 2026 at Zevra Therapeutics, down from $23.3 million in the prior quarter.
• Across five years, Receivables topped out at $23.3 million in Q4 2025 and bottomed at $3.1 million in Q2 2022.
• A 5-year average of $11.9 million and a median of $9.9 million in 2023 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 475.72% in 2022, while the deepest fall reached 70.64% in 2022.
• Zevra Therapeutics' Receivables stood at $9.4 million in 2022, then surged by 97.97% to $18.6 million in 2023, then slumped by 41.82% to $10.8 million in 2024, then surged by 114.52% to $23.3 million in 2025, then fell by 4.99% to $22.1 million in 2026.
• Business Quant data shows ZVRA's Receivables at $22.1 million in Q1 2026, $23.3 million in Q4 2025, and $16.8 million in Q3 2025.